
The COSMIC-313 study has developed a triplet regimen that incorporates all approved drugs targeting actionable targets in renal cell carcinoma. While this approach demonstrates higher clinical effectiveness compared to one of the standard doublet therapies, the potential for toxicities may restrict the proper administration of the drugs. Therefore, the study advises against the immediate adoption of this regimen.
Like
Save
Share